Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canada Ups Pricing Pressure on Biosimilars And Originators

This article was originally published in Scrip

Executive Summary

Manufacturers of biosimilars and originator/reference products are set to come under greater pressure to lower prices in Canada. In order to win reimbursement they will likely have to enter into pricing talks with the pan-Canadian Pharmaceutical Alliance (pCPA), which negotiates drug prices on behalf of Canada's public provincial and territorial drug plans. In a bid to develop a more competitive and transparent market for biosimilars, the pCPA has published its First Principles, aimed at guiding consistent negotiations for both biosimilars and their originator products.


Related Content

Canada Attempts Biosimilar Balancing Act





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts